Name: Latest research reports of Natco Pharma Ltd. authored by Edelweiss and published by - Trendlyne research reports.
Item: Natco Pharma Ltd.
Rating: 3
Author: Edelweiss

Natco Pharma Ltd.

NSE: NATCOPHARM | BSE: 524816 | ISIN: INE987B01026 | Industry: Pharmaceuticals
| Strong Performer, Under Radar

852.7500 -2.80 (-0.33%)

NSE Sep 05, 2025 15:31 PM

47.97% Fall from 52W High

Volume: 245.9K

Natco Pharma Ltd.

06 Nov 2017

852.75

-0.33%

Natco Pharmaceuticals Limited - Result Update Q2FY18

Hold: Natco Pharma Ltd.

Recommendation Target

Edelweiss

Natco Pharmaceuticals Limited (NATCO) Q2FY18: Underperformance led by pricing pressure across; exciting launches ahead.

Number of FII/FPI investors decreased from 385 to 317 in Jun 2025 qtr